Baillie Gifford & Co
HCAT icon

Baillie Gifford & Co’s Health Catalyst HCAT Stock Holding History

Baillie Gifford & Co’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-121,855
Closed -$992K – 276
2024
Q3 		$992K Sell
121,855
-308,742
-72% -$2.23M ﹤0.01% 254
2024
Q2 		$2.75M Sell
430,597
-106,171
-20% -$682K ﹤0.01% 239
2024
Q1 		$4.04M Sell
536,768
-1,550
-0.3% -$14.1K ﹤0.01% 242
2023
Q4 		$4.98M Sell
538,318
-28,818
-5% -$235K ﹤0.01% 239
2023
Q3 		$5.74M Sell
567,136
-23,318
-4% -$278K 0.01% 231
2023
Q2 		$7.38M Sell
590,454
-11,309
-2% -$135K 0.01% 229
2023
Q1 		$7.02M Buy
601,763
+2,851
+0.5% +$36.3K 0.01% 234
2022
Q4 		$6.37M Buy
598,912
+192,959
+48% +$1.86M 0.01% 238
2022
Q3 		$3.94M Buy
405,953
+13,436
+3% +$178K ﹤0.01% 247
2022
Q2 		$5.69M Sell
392,517
-47,650
-11% -$812K 0.01% 228
2022
Q1 		$11.5M Buy
440,167
+41,788
+10% +$1.19M 0.01% 230
2021
Q4 		$15.8M Buy
398,379
+17,376
+5% +$792K 0.01% 230
2021
Q3 		$19.1M Buy
381,003
+81,441
+27% +$4.44M 0.01% 227
2021
Q2 		$16.6M Buy
299,562
+36,732
+14% +$1.96M 0.01% 234
2021
Q1 		$12.3M Buy
262,830
+140,777
+115% +$6.82M 0.01% 237
2020
Q4 		$5.31M Buy
122,053
+59,738
+96% +$2.2M ﹤0.01% 231
2020
Q3 		$2.28M Buy
62,315
+56,328
+941% +$1.91M ﹤0.01% 229
2020
Q2 		$175K Buy
5,987
+2,635
+79% +$72.8K ﹤0.01% 238
2020
Q1 		$88K Buy
3,352
+860
+35% +$26.3K ﹤0.01% 219
2019
Q4 		$86K Hold
2,492
– – ﹤0.01% 220
2019
Q3 		$79K Buy
+2,492
New +$98.1K ﹤0.01% 220

Other funds holding HCAT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
DG
Daventry Group New York $133M AUM 32.28% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Baillie Gifford & Co's HCAT Position: Q4 2024 in Review

Baillie Gifford & Co sold out of Health Catalyst (HCAT) in Q4 2024, closing a stake of 121,855 shares — an estimated $992K sold.

Baillie Gifford & Co first reported a position in HCAT in Q3 2019 and held it in 21 quarters. The position peaked at $19.1M in Q3 2021. 167 funds tracked by Wall St. Rank hold HCAT as of Q4 2024.

  • Baillie Gifford & Co reported no remaining Health Catalyst position as of Q4 2024 after selling out during the quarter.
  • Baillie Gifford & Co sold 121,855 Health Catalyst shares in Q4 2024, an estimated $992K.
  • Baillie Gifford & Co first reported a position in Health Catalyst in Q3 2019 and held it in 21 quarters.
  • Baillie Gifford & Co's Health Catalyst position peaked at $19.1M in Q3 2021.
  • 167 funds tracked by Wall St. Rank held Health Catalyst as of Q4 2024.

Based on Baillie Gifford & Co's 13F filing for Q4 2024, filed 31 Jan 2025.